IL146508D0 - A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders - Google Patents

A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders

Info

Publication number
IL146508D0
IL146508D0 IL14650800A IL14650800A IL146508D0 IL 146508 D0 IL146508 D0 IL 146508D0 IL 14650800 A IL14650800 A IL 14650800A IL 14650800 A IL14650800 A IL 14650800A IL 146508 D0 IL146508 D0 IL 146508D0
Authority
IL
Israel
Prior art keywords
vla
treatment
use
monoclonal antibody
inflammatory disorders
Prior art date
Application number
IL14650800A
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US13703899P priority Critical
Priority to US18533600P priority
Application filed by Biogen Inc filed Critical Biogen Inc
Priority to PCT/US2000/015004 priority patent/WO2000072881A1/en
Publication of IL146508D0 publication Critical patent/IL146508D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
IL14650800A 1999-06-01 2000-06-01 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders IL146508D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13703899P true 1999-06-01 1999-06-01
US18533600P true 2000-02-29 2000-02-29
PCT/US2000/015004 WO2000072881A1 (en) 1999-06-01 2000-06-01 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
IL146508D0 true IL146508D0 (en) 2002-07-25

Family

ID=26834850

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14650800A IL146508D0 (en) 1999-06-01 2000-06-01 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
IL146508A IL146508A (en) 1999-06-01 2001-11-15 Blocking antibody to vla-1 and its use in the manufacture of a pharmaceutical composition for the treatment of inflammatory disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146508A IL146508A (en) 1999-06-01 2001-11-15 Blocking antibody to vla-1 and its use in the manufacture of a pharmaceutical composition for the treatment of inflammatory disorders

Country Status (28)

Country Link
US (5) US6955810B2 (en)
EP (3) EP1488806B1 (en)
JP (6) JP4817503B2 (en)
CN (1) CN1309419C (en)
AU (2) AU783989B2 (en)
BG (1) BG65579B1 (en)
BR (1) BR0011250A (en)
CA (1) CA2375827C (en)
CY (1) CY1116042T1 (en)
CZ (1) CZ300710B6 (en)
DK (2) DK1488806T3 (en)
EA (1) EA011384B1 (en)
EE (1) EE200100651A (en)
ES (2) ES2529706T3 (en)
GE (2) GEP20063774B (en)
HK (1) HK1154352A1 (en)
HU (1) HU0202568A3 (en)
IL (2) IL146508D0 (en)
IS (1) IS6179A (en)
MX (1) MXPA01012388A (en)
NO (1) NO20015864L (en)
NZ (1) NZ515686A (en)
PT (2) PT1488806E (en)
SI (2) SI1488806T1 (en)
SK (1) SK17232001A3 (en)
TR (1) TR200103432T2 (en)
WO (1) WO2000072881A1 (en)
YU (1) YU85501A (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20063774B (en) 1999-06-01 2006-03-27 Biogen Idec Inc Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
IL158376D0 (en) 2001-04-13 2004-05-12 Biogen Inc Antibodies to vla-1
AU2003215298A1 (en) * 2002-02-14 2003-09-04 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
US7348002B2 (en) * 2002-11-01 2008-03-25 Boys Town National Research Hospital Inducible ligand for α1β1 integrin and uses
WO2005004800A2 (en) * 2003-06-20 2005-01-20 Morehouse School Of Medicine Trypanosome derived apoptotic factors (taf)
WO2005057755A1 (en) * 2003-12-09 2005-06-23 Electrotechnologies Selem, Inc. Polyphase claw-pole machines with a segmented magnetic circuit
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) * 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
PT2034830E (en) 2006-05-25 2014-10-14 Biogen Idec Inc Anti-vla-1 antibody for treating stroke
EP2279209A2 (en) * 2008-05-09 2011-02-02 Ablynx NV Amino acid sequences directed against integrins and uses thereof
ES2732243T3 (en) 2012-02-16 2019-11-21 Santarus Inc Pharmaceutical compositions of ANTI-VLA1 antibodies (CD49A)
WO2019018688A1 (en) * 2017-07-20 2019-01-24 The University Of Virginia Patent Foundation Methods for treatment or prevention of a neurological immunity disorder

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69230142T2 (en) 1991-05-15 2000-03-09 Cambridge Antibody Tech A process for the preparation of specific binding pair members
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993013798A1 (en) 1992-01-13 1993-07-22 Biogen, Inc. Treatment for asthma
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6307026B1 (en) 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
WO1994016094A2 (en) 1993-01-12 1994-07-21 Biogen, Inc. Recombinant anti-vla4 antibody molecules
DK0682529T4 (en) 1993-02-09 2006-05-15 Biogen Idec Inc Antibody for the treatment of insulin-requiring diabetes
US6111598A (en) 1993-11-12 2000-08-29 Peveo, Inc. System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0804237B8 (en) 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
DE69518415D1 (en) 1994-04-26 2000-09-21 Kanebo Ltd Drug for rheumatoid arthritis
JPH08131185A (en) * 1994-11-14 1996-05-28 Sumitomo Electric Ind Ltd Monoclonal antibody against murine vla-1 molecule
JPH08160972A (en) 1994-12-01 1996-06-21 Sega Enterp Ltd Method and device for effect control and karaoke device utilizing the device
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
GB9516399D0 (en) 1995-08-10 1995-10-11 Camelot Superabsorbents Ltd Process for the production of water-absorbing compositions
AT219517T (en) 1995-08-18 2002-07-15 Morphosys Ag Protein - / (poly) peptide libraries
DK0843961T3 (en) 1995-08-29 2007-05-21 Kirin Brewery Chimeric mouse and method of producing same
DE19534177A1 (en) 1995-09-15 1997-03-20 Merck Patent Gmbh cyclic adhesion inhibitors
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (en) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt A process for producing human antibodies and their use
FR2745912B1 (en) * 1996-03-08 1998-05-29 Lorraine Laminage Method and control device of weldability sandwich toles
US6127524A (en) 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
AU740284B2 (en) 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
WO1999061040A2 (en) 1998-05-22 1999-12-02 Boys Town National Research Hospital USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE
DE19831710A1 (en) 1998-07-15 2000-01-20 Merck Patent Gmbh New diacyl-hydrazine derivatives, are integrin inhibitors useful for treating e.g. thrombosis, cardiac infarction, tumors, osteoporosis, inflammation or infection
CA2340333A1 (en) 1998-10-06 2000-04-13 Biogen, Inc. Crystals of the alpha 1 beta 1 integrin i-domain and their use
IL145898D0 (en) * 1999-04-22 2002-07-25 Biogen Inc Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
GEP20063774B (en) * 1999-06-01 2006-03-27 Biogen Idec Inc Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
AU4545600A (en) 1999-06-17 2001-01-09 Kai Desinger Surgical, grooved director for collecting tissue in a minimally invasive manner
WO2001073444A2 (en) 2000-03-28 2001-10-04 Cambridge University Technical Services Limited Receptor/peptide crystal structure for identification of inhibitors
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DE10028402A1 (en) 2000-06-13 2001-12-20 Merck Patent Gmbh New pyridinylamino-alkanoyl-glycyl-beta-alanine derivatives, are integrin inhibitors useful for treating, e.g. thrombosis, cardiac infarction, coronary heart disease, inflammation, tumors, osteoporosis or restenosis
WO2002009737A1 (en) 2000-07-31 2002-02-07 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
IL158376D0 (en) 2001-04-13 2004-05-12 Biogen Inc Antibodies to vla-1
AU2003215298A1 (en) 2002-02-14 2003-09-04 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
US7300655B2 (en) 2002-08-01 2007-11-27 Immunomedics, Inc. Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
WO2005019200A2 (en) 2003-08-14 2005-03-03 Icos Corporation Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
WO2005016883A2 (en) 2003-08-14 2005-02-24 Icos Corporation Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
JO3324B1 (en) 2006-04-21 2019-03-13 Amgen Inc Lyophilized Therapeutic Peptibody Formulations
PT2034830E (en) 2006-05-25 2014-10-14 Biogen Idec Inc Anti-vla-1 antibody for treating stroke
JP4951596B2 (en) 2008-07-31 2012-06-13 株式会社日立製作所 Cooling system and electronic device
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
MX361668B (en) 2009-12-21 2018-12-11 Genentech Inc Antibody formulation.
WO2012106497A2 (en) 2011-02-03 2012-08-09 Santarus, Inc. Selection and treatment of subjects
EP2804208A4 (en) 2012-01-11 2015-07-29 Panasonic Ip Man Co Ltd Pressure contact type semiconductor device and method for fabricating same
ES2732243T3 (en) 2012-02-16 2019-11-21 Santarus Inc Pharmaceutical compositions of ANTI-VLA1 antibodies (CD49A)

Also Published As

Publication number Publication date
NO20015864D0 (en) 2001-11-30
US20090324598A1 (en) 2009-12-31
BG106226A (en) 2002-08-30
US20120087925A1 (en) 2012-04-12
EP1488806A2 (en) 2004-12-22
CZ20014249A3 (en) 2002-06-12
JP2007277253A (en) 2007-10-25
HK1154352A1 (en) 2015-09-25
CN1390137A (en) 2003-01-08
JP5960762B2 (en) 2016-08-02
DK1488806T3 (en) 2016-02-08
SK17232001A3 (en) 2002-09-10
EA200400930A1 (en) 2004-12-30
US20050226877A1 (en) 2005-10-13
GEP20063774B (en) 2006-03-27
IS6179A (en) 2001-11-28
EA011384B1 (en) 2009-02-27
JP2011157403A (en) 2011-08-18
HU0202568A2 (en) 2002-11-28
SI2314315T1 (en) 2015-04-30
EE200100651A (en) 2003-02-17
JP2012176983A (en) 2012-09-13
WO2000072881A1 (en) 2000-12-07
MXPA01012388A (en) 2002-07-30
YU85501A (en) 2004-07-15
US9902774B2 (en) 2018-02-27
EP1488806A3 (en) 2011-03-30
GEP20043233B (en) 2003-11-10
US7462353B2 (en) 2008-12-09
ES2557768T3 (en) 2016-01-28
EP1488806B1 (en) 2015-12-09
NO20015864L (en) 2002-02-01
BG65579B1 (en) 2009-01-30
IL146508A (en) 2007-08-19
SI1488806T1 (en) 2016-02-29
BR0011250A (en) 2002-03-05
JP5623335B2 (en) 2014-11-12
TR200103432T2 (en) 2002-10-21
US20020146417A1 (en) 2002-10-10
US6955810B2 (en) 2005-10-18
NZ515686A (en) 2005-01-28
JP2016121184A (en) 2016-07-07
HU0202568A3 (en) 2009-11-30
JP2004500328A (en) 2004-01-08
CY1116042T1 (en) 2017-01-25
CA2375827A1 (en) 2000-12-07
ES2529706T3 (en) 2015-02-24
US20140154259A1 (en) 2014-06-05
DK2314315T3 (en) 2015-02-02
PT2314315E (en) 2015-03-17
CZ300710B6 (en) 2009-07-22
EP2314315A1 (en) 2011-04-27
EP1181054A1 (en) 2002-02-27
CN1309419C (en) 2007-04-11
AU783989B2 (en) 2006-01-12
PT1488806E (en) 2016-02-26
EP2314315B1 (en) 2015-01-21
JP2014210818A (en) 2014-11-13
CA2375827C (en) 2017-01-10
AU2006201540A1 (en) 2006-05-11
US8557240B2 (en) 2013-10-15
JP4817503B2 (en) 2011-11-16
US8084031B2 (en) 2011-12-27
AU5724800A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
DE69725484D1 (en) Device for the treatment of urinary incontinence
DE60037245D1 (en) Pressure-controlled device for the continuous closing of the coronarsinus
DE60105035D1 (en) 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic use
DK1666052T3 (en) Anti-APRIL monoclonal antibody and its use in the treatment of an immune-related disease or cancer
DK1351703T3 (en) Use of a polypeptide comprising the extracellular domain of IL-20RA and IL-20RB for the treatment of inflammation
DE60138019D1 (en) Use of triglycerides with medium-wide chains for the treatment and prevention of alzheimer's disease
DE69724016D1 (en) Use of anti-microtubuli for treating inflammatory diseases of the breathways
DK0964663T3 (en) Device for preventing snoring or snoring
DE60026627D1 (en) reboxetine for the treatment of fibromyalgia and other somatoform disorders
DE69905938T2 (en) Combination of duloxetin with non-steroid inflammatory inhibitors for the treatment of pain
GB2259451B (en) Genital-vulva pad sanitary napkin construction
DK1911442T3 (en) Preparation for the prevention and / or treatment of vascular disorders
DE69722426D1 (en) Isobutylgaba and its derivatives for the treatment of pain
DK1041990T3 (en) Composition for the treatment of respiratory and skin diseases with at least one leukotriene antagonist and at least one antihistamine
DE60123041D1 (en) Anti-inflammatory compounds and their use
DK0799037T3 (en) Preparation for the treatment of allergic rhinitis and other disorders, including descarboethoxyloratadine
DE60033947D1 (en) Dosage form and method for effective reboxetine therapy with "one daily" dosage
DE69432243D1 (en) 2-phenyl-3-aroylbenzothiophenes for the treatment of menstrual symptoms
DE69217364T3 (en) Sanitary napkin with shaping agent
DK1148873T3 (en) Highly purified ethyl EPA and other EPA derivatives against neurological disorders
DK1165110T3 (en) Antagonists of HMG1 for the treatment of inflammatory conditions
DE60226702D1 (en) Long acting glucagon-similar peptide-2 for the treatment of gastrointestinal diseases and disorders
DE69535253D1 (en) Humanized antibodies to the respiratory syncytialvirus
DE60042693D1 (en) Dosage for treatment with anti erbb2 antibodies
DK0719859T3 (en) Anti-alpha V integrin monoclonal antibody

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed